NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the tale to a close.
In 2014, Theranos founder and CEO Elizabeth Holmes used to be widely seen as the following Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the entire range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There used to be only one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and needless treatments. All of the even as, Holmes and her partner, Sunny Balwani, worked to silence someone who voiced misgivings—from journalists to their very own employees.
“Chilling … Reads like a thriller … Carreyrou tells [the Theranos story] virtually to perfection.” —
The New York Times Book ReviewIn 2014, Theranos founder and CEO Elizabeth Holmes used to be widely seen as the following Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the entire range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There used to be only one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and needless treatments. All of the even as, Holmes and her partner, Sunny Balwani, worked to silence someone who voiced misgivings—from journalists to their very own employees.
Reviews
There are no reviews yet.